Wikipedia -WSS

Wikipedia

author：hotspot 2025-09-30 17:02:45 - browse：68

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： The untold story of TV’s first prescription drug ad

focus

WSS

GSK to buy asthma

Three issues to watch in global health in 2024

Change Healthcare: What is it, why does its cyberattack matter?

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

For AI in health care standards, federal regulators join with industry group

Change Healthcare: What is it, why does its cyberattack matter?

focus

Wikipedia

Wikipedia

Virginia high school admissions case could be legal follow

New England Journal of Medicine addresses racist history, slavery

Hepatitis C has a cure — but many Americans still lack access to it

Designating disabled people as health disparity population is crucial

How one medical school became remarkably diverse

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

In Memoriam: Notable people who died in 2023

The SUPPORT Act is critical to fighting the opioid crisis

At least 13 dead in Texas as scorching temps continue

Medicare drug price negotiation continues, as pharma counteroffers

entertainment

$1 billion proposal to grow Boston, Massachusetts biotech

Microsoft's Peter Lee: Generative AI could help doctors be more human

Longer MASH drug regimen improved liver, Akero study finds

He's 19 months old and has one of the world’s rarest diseases

New menopause drug shows promise in relief for hot flashes

Readout Newsletter: BridgeBio, Akero, and human embryo models

knowledge

focus

focus

focus